Daily levothyroxine (LT4) is the standard of care for the treatment of hypothyroidism; however, a small number of patients experience residual symptoms of hypothyroidism. Guidelines indicate that a trial with LT4 and liothyronine (LT3) could be attempted once other conditions have been addressed or excluded. Even so, currently, treatment of hypothyroidism can still be suboptimal.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Impaired autonomic function and somatosensory disturbance in patients with treated autoimmune thyroiditis
Scientific Reports Open Access 29 May 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bianco, A. C. Rethinking Hypothyroidism (Univ. Chicago Press, 2022).
Penna, G. C., Bensenor, I. M., Bianco, A. C. & Ettleson, M. D. Thyroid hormone homeostasis in levothyroxine-treated patients: findings from ELSA-Brasil. J. Clin. Endocrinol. Metab., https://doi.org/10.1210/clinem/dgae139 (2024).
Idrees, T., Palmer, S., Maciel, R. M. B. & Bianco, A. C. Liothyronine and desiccated thyroid extract in the treatment of hypothyroidism. Thyroid 30, 1399–1413 (2020).
Jonklaas, J. et al. Evidence-based use of levothyroxine/liothyronine combinations in treating hypothyroidism: a consensus document. Thyroid 31, 156–182 (2021).
Shakir, M. K. M. et al. Comparative effectiveness of levothyroxine, desiccated thyroid extract, and levothyroxine+liothyronine in hypothyroidism. J. Clin. Endocrinol. Metab. 106, e4400–e4413 (2021).
Dumitrescu, A. M. et al. Extended absorption of liothyronine from poly-zinc-liothyronine: results from a phase 1, double-blind, randomized, and controlled study in humans. Thyroid 32, 196–205 (2022).
Ettleson, M. D. et al. Demographic, healthcare access, and dietary factors associated with thyroid hormone treatments for hypothyroidism. J. Clin. Endocrinol. Metab. 108, e1614–e1623 (2023).
Taylor, P. N. et al. Falling threshold for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: evidence from a large community-based study. JAMA Intern. Med. 174, 32–39 (2014).
Ahluwalia, R. et al. Use of liothyronine (T3) in hypothyroidism: joint British Thyroid Association/Society for Endocrinology consensus statement. Clin. Endocrinol. 99, 206–216 (2023).
Taylor, P. N. et al. Liothyronine cost and prescriptions in England. Lancet Diabetes Endocrinol. 7, 11–12 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.C.B. is a consultant for AbbVie, Acella, Synthonics. P.N.T. declares no competing interests.
Rights and permissions
About this article
Cite this article
Bianco, A.C., Taylor, P.N. Optimizing the treatment of hypothyroidism. Nat Rev Endocrinol (2024). https://doi.org/10.1038/s41574-024-00989-7
Published:
DOI: https://doi.org/10.1038/s41574-024-00989-7